References
- Sanz de Burgoa V, Rejas J, Ojeda P. Investigators of the CosteAsma study. Self-perceived sleep quality and quantity in adults with asthma: findings from the CosteAsma study. J Investig Allergol Clin Immunol 2016;26:256–262.
- Svedsater H, Hilton E, Leather D, T Robinson, L Bradshaw, H Doll, et al. Evaluation and quantification of treatment preferences for patients with asthma or COPD using discrete choice experiment surveys. Thorax 2016;71(Suppl 3):A161–A162.
- Global Initiative for Asthma (GINA). 2016 GINA Report, Global Strategy for Asthma Management and Prevention. Available from: http://ginasthma.org
- Raherison C, Abouelfath A, Le Gros V, Taytard A, Molimard M. Underdiagnosis of nocturnal symptoms in asthma in general practice. J Asthma 2006;43:199–202.
- Bleecker ER, Lötvall J, O'Byrne PM, Woodcock A, Busse WW, Kerwin EM, et al. Fluticasone furoate-vilanterol 100–25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial. J Allergy Clin Immunol Pract 2014;2:553–561.
- O'Byrne PM, Bleecker ER, Bateman ED, Busse WW, Woodcock A, Forth R, et al. Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma. Eur Respir J 2014;43:773–782.
- Bernstein DI, Bateman ED, Woodcock A, Toler WT, Forth R, Jacques L, et al. Fluticasone furoate (FF)/vilanterol (100/25 mcg or 200/25 mcg) or FF (100 mcg) in persistent asthma. J Asthma 2015;52:1073–1083.
- Braithwaite I, Williams M, Power S, Pilcher J, Weatherall M, Baines A, et al. Randomised, double-blind, placebo-controlled, cross-over single dose study of the bronchodilator duration of action of combination fluticasone furoate/vilanterol inhaler in adult asthma. Respir Med 2016;119:115–121.
- Bateman ED, O'Byrne PM, Busse WW, Lötvall J, Bleecker ER, Andersen L, et al. Once-daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone. Thorax 2014;69:312–319.
- Allen A, Schenkenberger I, Trivedi R, Cole J, Hicks W, Gul N, et al. Inhaled fluticasone furoate/vilanterol does not affect hypothalamic-pituitary-adrenal axis function in adolescent and adult asthma: randomised, double-blind, placebo-controlled study. Clin Respir J 2013;7:397–406.
- Dissanayake S, Jain M, Grothe B, McIver T, Papi A. An evaluation of comparative treatment effects with high and low dose fluticasone propionate/formoterol combination in asthma. Pulm Pharmacol Ther 2015;35:19–27.
- Weinstein SF, Corren J, Murphy K, Nolte H, White M. Twelve-week efficacy and safety study of mometasone furoate/formoterol 200/10 µg and 400/10 µg combination treatments in patients with persistent asthma previously receiving high-dose inhaled corticosteroids. Allergy All Proc 2010;31:280–289.
- Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ, Pauwels RA, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 2004;170:836–844.
- Aalbers R, Vogelmeier C, Kuna P. Achieving asthma control with ICS/LABA: a review of strategies for asthma management and prevention. Respir Med 2016;111:1–7.